Novartis Venture Fund
Foster innovation, drive significant patient benefit and generate superior returns by creating and investing in innovative life science companies.
NVF is stage agnostic, engaging in investments from seed- to later-stage life sciences companies across Biotechnology/Biopharma.
Our primary focus is on the development of novel therapeutics and platforms. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program.
We invest in North America, Europe, Israel and Asia/Pacific with approximately USD 800 million under management in committed capital and more than 24 portfolio companies. We continue our strategy of making larger focused investments and anticipate total investments up to USD 30 million per company over its life.
We make equity investments in Biotechnology/Biopharma life sciences companies. NVF is stage agnostic and engages in seed investments as well as later-stage investments. We typically lead or co-lead an investment and play an active role on company boards.
number of jobs created
dollars under management approximately $800 million
Phase 1 and 2 clinical programs
Dr. Laura Brass is a Managing Director at the Novartis Venture Fund in Cambridge, MA, USA. Prior to joining NVF, Laura was a Managing Director at MPM Capital, and prior to that, she was a member of the founding management team and SVP of Business Development for TriNetX, a healthcare IT company focusing on big data analytics for clinical research. Before TriNetX, Laura was Director of Business Development at Harvard University’s Office of Technology Development and at its Wyss Institute for Biologically Inspired Engineering. She led commercialization strategy, start-up creation, deal structuring, and negotiations for a portfolio of over 250 biotech, synthetic chemistry, engineering, software, device, and stem cell technologies developed at Harvard and Harvard-affiliated institutions. Laura has also held roles in business development and IP strategy at Elixir Pharmaceuticals, and was CEO of Aferon, Inc., an early-stage antiviral start-up company. Laura holds a B.A. in Philosophy and a B.S. in Biochemistry from the University of Missouri-Columbia, and a Ph.D. in Molecular Genetics and Cell Biology and an M.B.A. from the University of Chicago.
Annexon (Observer) Anokion (Board Seat) E-Scape Bio (Board Seat) Immunitas Therapeutics (Board Seat)
Bart Dzikowski is a Managing Director at the Novartis Venture Fund and its Head of Transactions & Legal based in Basel, Switzerland. Prior to joining NVF, Bart held various senior roles in Novartis’ Corporate Legal M&A and Business Development & Licensing groups. Before joining Novartis in 2009, Bart was a Vice President with the Investment Banking Division of Bank of America/Merrill Lynch in New York and, before that, he was an attorney with the Corporate/M&A Group at the law firm of Allen & Overy LLP in New York. Bart holds degrees in common law (LL.B.) and civil law (B.C.L.) from McGill Law School in Canada and is a member of the New York State Bar.
Enterprise Therapeutics (Board Seat) Inflazome (Board Seat) Oculis (Board Seat)
Dr. Anja König is the Global Head of the Novartis Venture Fund in Basel, Switzerland. Previously, she was a Managing Director at NVF investing in Switzerland, U.K. and the rest of Europe as well as Asia/Pacific. Prior to joining NVF, she was an Associate Partner at McKinsey and Company in New York, where she worked with healthcare companies in the US, Europe and Emerging Markets. Anja holds a PhD in physics from Cornell University. She is active in the Swiss startup ecosystem and is a member of the board of the University of Zurich Life Sciences Fund, the evaluation panel of the Bridge Grant POC program of the Swiss National Science Foundation and the CTI, the selection committee of BaseLaunch and serves as a coach with the ETH Pioneer Labs program.
Anaveon (Observer) Arctos (Board Seat) Forendo Pharma, Ltd. (Board Seat) Ribon Therapeutics (Board Seat)
Bicycle Therapeutics (IPO) Covagen AG (Acquired by J&J) Genedata (Buy Back) Heptares Therapeutics, Ltd (Acquired by Sosei) Nabriva Therapeutics (IPO) PharmAbcine (IPO) Qurient Therapeutics (IPO)
Dr. Campbell Murray is a Managing Director at the Novartis Venture Fund in Cambridge, MA, USA. Prior to joining NVF, he worked at the Novartis Institutes for BioMedical Research as the Director of Special Projects. Campbell is a New Zealand-trained physician and worked as a Medical House Officer at Auckland Hospital. He is a Kauffman Fellow and holds an MBA from Harvard Business School and an MPP (public policy) from the John F. Kennedy School of Government, where he was a Knox Fellow and Rotary Ambassadorial Scholar.
Annexon, Inc. (Board Seat) Expansion Therapeutics (Board Seat) Lemonaid Health, Inc. (Board Seat) Renovacor (Board Seat) TScan Therapeutics (Board Seat)
Aerpio Therapeutics (IPO) Akebia Therapeutics (IPO) Akouos (IPO) Alios BioPharma, Inc. (Acquired by J&J) Tokai Pharmaceuticals (IPO) Neurovance, Inc. (Acquired by Otsuka)
Dr. David Morris is an Operating Partner at the Novartis Venture Fund in San Francisco, CA, USA, while also serving as the Chief Medical Officer of Enterprise Therapeutics, one of NVF’s portfolio companies. Prior to joining NVF, he held multiple leadership roles in the Novartis Pharmaceuticals development organization including the Development Franchise Head of Respiratory, Development Franchise Head of Primary Care and, most recently, Global Head of Clinical Operations, Analytics and Regions where he was responsible for clinical trials operations and monitoring, statistics, data management, medical writing, submissions management and digital innovation. Prior to joining Novartis in 2009, David worked in drug discovery and translational medicine at Roche in Palo Alto, California. Before joining industry, he was a faculty member at Yale University Medical School and, prior to that, the University of California, San Francisco (UCSF) Medical School. David received his Bachelors and Medical Degrees with distinction from the University of Rochester Medical School and trained in internal medicine at the Massachusetts General Hospital and in Pulmonary and Critical Care Medicine at UCSF. He did his postdoctoral research training at the Lung Biology Center and Cardiovascular Research Institute at UCSF.
Enterprise Therapeutics (CMO) Inflazome (Observer)
Dr. Florian Muellershausen is a Managing Director at the Novartis Venture Fund in Basel, Switzerland. Prior to joining Novartis Venture Fund, he worked as a Scientific Manager for the R&D Committee of the Novartis Board of Directors and, before that held various scientific and drug discovery roles at the Novartis Institute of Biomedical Research (NIBR) including as Laboratory Head in target discovery and in early clinical research as Translational Medicine Expert, Autoimmunity. Florian received his MSc degree in Biochemistry from Free University Berlin and his PhD degree with great distinction in Biochemistry from Ruhr University Bochum and completed his post-doctoral training at NIBR in Switzerland.
Anaveon (Board Seat) Forendo ( Observer) FoRx Therapeutics (Board Seat)
Dr. Aaron Nelson is a Principal at the Novartis Venture Fund in Cambridge, MA, USA. Prior to joining NVF, he was an investor at dRx Capital, the joint investment company of Novartis and Qualcomm, focused on Digital Medicine. Previously, Aaron worked on technology strategy across multiple Business Units within Novartis, including Strategic Project Leader for the Trials of The Future program and Group Head in the Investigative Toxicology organization. Aaron studied medicine at Tufts University, cell and microbiology at the University of Pennsylvania and the Karolinska Institutet, and completed his undergraduate studies at Cornell University.
Exo Therapeutics (Board Seat) ImmPACT-Bio (Observer) Lemonaid Health (Observer)
Dr. Nandita Shangari is a Principal at the Novartis Venture Fund in Cambridge, MA USA. Prior to joining NVF, she was part of the Novartis Oncology Business Development and Licensing team where she managed key alliances for the Oncology Portfolio. Before that, Nandita, held the Global Program Team Director position as part of the Kymriah® Global Program Team and helped bring this novel cell therapy to market, for two indications, in the US and EU. Nandita has also held strategic and group head roles in the Novartis Preclinical Investigative Toxicology organization. Nandita received her B.Sc. in Biochemistry and Ph.D. in Pharmaceutical Sciences from the University of Toronto, Canada.
Immunitas Therapeutics (Observer) Renovacor (Observer)
Michal Silverberg is a Managing Director at the Novartis Venture Fund in Cambridge, MA, USA. Prior to joining NVF, she was a Senior Partner at Takeda Ventures and, before that, worked at Novo Nordisk in roles of increasing responsibility including as Senior Director Business Development and New Product Commercialization, serving as a member of the BioPharm leadership team. Since 1998, Michal has held positions in various sectors of the life science industry including in the Office of the Chief Scientist of Israel (The Incubator program), venture capital (Ofer Brothers Hi Tech) and global pharmaceutical and biotech companies, including various positions at MGVS, an Israeli biotech company and at OSI Pharmaceuticals in a business development role. She received her B.A. in Economics and Business Management from Haifa University, her M.B.A from Tel-Aviv University in Israel and her Master's degree in Biotechnology from Columbia University in New York.
Adicet Bio (Board Seat) ImmPACT-Bio (Board Seat) Twentyeight-Seven (Board Seat)
Cavion (Acquired by Jazz Pharmaceuticals) Forma Therapeutics (IPO) Viamet Therapeutics (Acquired by NovaQuest Capital Management)
Prof. Patrick Aebischer is President emeritus of the École Polytechnique Fédérale de Lausanne (EPFL) and a member of its Brain Mind Institute. Patrick Aebischer trained as an MD (1980) and a Neuroscientist (1983) at the Universities of Geneva and Fribourg in Switzerland. Prior to joining EPFL, he held Faculty positions at Brown University and the University of Lausanne. He has received numerous honors, including the Robert Bing Prize of the Swiss Academy of Medicine and the Pfizer Foundation Prize for Clinical Neurosciences. He serves as a Senate Member of the "Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE). He is a member of the scientific committee of the Italian Institute of Technology and a member of the Singapore Biomedical Sciences International Advisory Council. Prof. Aebischer is a member of the Board of Lonza, Nestlé and Logitech and a founder of three biotech companies. He is a senior partner of NanoDimension-III.
Professor School of Life Sciences, Ecole Polytechnique FÃ©dÃ©rale de Lausanne (EPFL); former Director of the Swiss Institute for Experimental Cancer Research (ISREC); Director of the National Center of Competence in Research (NCCR) in Molecular Oncology.
Harry Kirsch is the Chief Financial Officer of Novartis and a member of the Executive Committee of Novartis. Prior to his current position, he served as CFO of the company's Pharmaceuticals Division. Under his leadership, the division's core operating income margin increased, in constant currencies, every quarter of 2011 and 2012 despite patent expirations. Harry joined Novartis in 2003 from Procter & Gamble in the United States, where he was a CFO of P&G's global pharmaceutical business and held various finance positions at divisional, regional, country and manufacturing site level, as well as in P&G Global Business Services organization. Harry also represents Novartis on the board of the GSK Consumer Healthcare joint venture. Harry holds a degree in industrial engineering and economics from the University of Karlsruhe in Germany.
Nobel Prize Winner for Chemistry, Collège de France, Paris, Université Louis Pasteur, Strasbourg, France.
Director of Research, Institut Curie, Paris, France.
Dr. Christoph A. Meier is the Chief Medical Officer at the University Hospital Basel and Professor at the Medical Faculty of the University of Geneva. Prior to his current role, he was the Chief of the Department of Internal Medicine & Specialties and a member of the Board of Directors at Triemli Hospital in Zurich, Switzerland, as well as Chief of Endocrinology and Head of the Laboratory of Molecular Endocrinology at the University Hospital Geneva. Dr. Meier received his Medical Degree from the University of Basel in Switzerland and holds his Swiss Board Certification (FMH) in Internal Medicine and Endocrinology & Diabetology. Dr. Meier completed his medical residency at the University Hospital of Geneva and was a a Postdoctoral Fellow at the National Institutes of Health in the Molecular, Cellular Nutritional Endocrinology Branch in Bethesda, MD (USA). He was also a Howard Hughes Medical Institute Physician Fellow at the Division of Genetics, Brigham and Women's Hospital, as well as a Clinical Fellow in Endocrinology, Diabetes and Metabolism at the Massachusetts General Hospital, Harvard Medical School.
Professor of Biology, Massachusetts Institute of Technology; Member, Whitehead Institute for Biomedical Research.
Dr. Beat Steffen is a Principal at the Novartis Venture Fund in Basel, Switzerland. Prior to joining NVF, he worked at Novartis Pharmaceuticals in commercial roles in the US and in Switzerland launching several products mainly in the cardiovascular area. Beat joined Novartis from Wellington Partners Venture Capital where he worked with biotech and medical device startup companies. Prior to that, he was at McKinsey & Company in Zurich working with clients in the pharmaceutical industry. Beat is a Swiss-trained physician having focused in cardiovascular surgery and intensive care. He graduated from the University of Zurich Medical School and qualified as a Medical Doctor in Basel. Beat holds an MBA with distinction from INSEAD.
Vivet (Board Seat) Binx (Board Seat) Artios (Board Observer)
Dr. Marianne Uteng is an Associate at the Novartis Venture Fund in Basel, Switzerland. Prior to joining NVF, she worked in Novartis Global Drug Development and, before that, in the Pre-Clinical Safety Department at the Novartis Institutes of Biomedical Research, where she led teams delivering health authority-required and non-routine safety assessments for early and late stage programs across many therapeutic areas. Concurrently, she supported the Novartis BD&L Search & Evaluation Team, and spearheaded collaborations with biotechnology companies and academia for development of innovative in vitro/in vivo systems. Marianne received her MSc in biochemistry from the University of Oslo and her PhD in molecular biology, cell biology and biophysics from a joint program between European Molecular Biology Laboratories and the University of Oslo.
Dr. James (Jay) Bradner, M.D., is the President of the Novartis Institutes for BioMedical Research (NIBR) and a member of the Executive Committee of Novartis. From 2005 through 2015, Dr. Bradner served on the research faculty of Harvard Medical School and as an attending physician in stem cell transplantation within the Department of Medical Oncology at the Dana-Farber Cancer Institute in the United States. He has co-founded five biotechnology companies and has co-authored more than 200 scientific publications and 30 US patent applications. Dr. Bradner is a graduate of Harvard College and the University of Chicago Medical School in the US. He completed his residency in medicine at Brigham and Women's Hospital, his fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute, and his postdoctoral training in chemistry and chemical biology at Harvard University. He has received many honorific awards and was elected into the American Society for Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013.
Dr. Michael Gilman is a scientist, general manager, biotech executive and serial entrepreneur. Mike currently serves on the Boards of Directors of Scholar Rock, X4 Pharmaceuticals, Obsidian Therapeutics and Arrakis Therapeutics, where he is also the Chairman of the Board and Chief Executive Officer. He also serves on the Scientific Advisory Board of FutuRx, a biotech accelerator. Previously, Mike was a Founder and CEO of Padlock Therapeutics, a venture-funded company focused on autoimmune disease, acquired by Bristol-Myers Squibb in 2016. Prior to Padlock, Mike served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec, with responsibility for managing the company`s development programs through clinical proof-of-concept. He joined Biogen Idec in March 2012 following its acquisition of Stromedix, a venture-backed company focused on fibrosis and organ failure, where he was Founder and CEO. Prior to founding Stromedix in 2006, Mike served as Executive Vice President, Research at Biogen Idec, with responsibility for the company`s discovery research activities in Cambridge and San Diego. From 1994 to 1999, Mike was at ARIAD Pharmaceuticals, where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Mike was on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation. Mike was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a Ph.D in Biochemistry from University of California, Berkley, and a S.B. in Life Science from Massachusetts Institute of Technology.
Dr. Elaine Jones is an experienced biopharmaceutical executive with more than 20 years of investment experience as a life science-focused venture capitalist. She currently serves on the boards of several public companies, is the Chair of Mironid (UK), and serves as an advisor to InnovateUK, the UK’s innovation agency. She was most recently Vice President, Venture Capital at Pfizer Ventures, the corporate venture capital arm of Pfizer, where she was responsible for managing biotechnology and healthcare investments for Pfizer, as well as serving on the board of directors of several biotech companies. Prior to Pfizer, Dr. Jones was a General Partner with EuclidSR Partners, a venture fund focused on the life sciences and technology sectors, as well as in areas where those industries converge to enhance drug discovery, development and marketing. She began her investing career in 1999 at S.R. One, the corporate investment fund of GlaxoSmithKline. During her venture career, she served on the boards of more than 20 early to mid-stage biotechnology, therapeutic and pharmaceutical companies. Previously, she was the Director of Scientific Licensing at SmithKline Beecham and a research scientist in the research and development division of SmithKline Beecham Pharmaceuticals. Dr. Jones received a B.S. in Biology from Juniata College and a Ph.D. in Microbiology from the University of Pittsburgh and conducted post-doctoral research at the National Institutes of Health, in the National Institute of Allergy and Infectious Disease.
Dr. John Tsai, M.D., is the Head of Global Drug Development and Chief Medical Officer for Novartis and a member of the Executive Committee of Novartis. Dr. Tsai joined Novartis from Amgen Inc., where he was chief medical officer and senior vice president of Global Medical, overseeing all clinical and medical functions across multiple sites worldwide. Before joining Amgen in 2017, he spent 11 years at Bristol-Myers Squibb Co. (BMS), most recently as global head of clinical development for marketed products. During his time at BMS, Dr. Tsai also served as a full development team lead in oncology, head of Worldwide Medical, chief medical officer for Europe, vice president of US Medical, and vice president of Cardiovascular Medical. Prior to BMS, he was a cardiovascular group leader at Pfizer Inc. He started his career as an electrical engineer at General Electric Co. Dr. Tsai holds a medical degree from the University of Louisville School of Medicine in the United States. He received a Bachelor of Science in electrical engineering from Washington University in St. Louis, also in the US..
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.
Anaveon is developing a selective IL-2 Receptor Agonist for the treatment of cancer.
Arctos Medical is a spin-off company from the University of Bern and is developing gene therapy approaches for ophthalmological diseases.
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.
Ribon Therapeutics is a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.
Oculis is a clinical – stage, privately held, pharmaceutical development company focusing on opthalmic drugs and novel drug delivery to the eye.
Renovacor is a preclinical stage biotechnology company whose mission is to develop improved therapies for genetically derived cardiovascular diseases. The company is currently developing a gene therapy for a rare, familial form of dilated cardiomyopathy. Renovacor’s lead gene therapy product aims to restore cardiac function in patients with symptomatic heart failure due to BAG3 gene mutation.
Lemonaid Health is leading a second wave of telehealth where technology algorithms power quality care. Lemonaid leverages evidence-based guidelines and the most up-to-date clinical protocols to offer a service direct to consumer for less than typical co-pays. Lemonaid is focused on creating a revolutionized patient experience and improving and optimizing clinical care through the advancements in machine learning and AI.
Vivet Therapeutics SAS is addressing current gene therapy limitations and focusing on the discovery and clinical development of gene therapy for liver inherited metabolic diseases as well as for protein replacement therapy. A treatment of the Wilson’s disease has entered GMP manufacturing and IND enabling studies. Additional programs are being developed, including for treatment of progressive familial intrahepatic cholestasis and Citrulinemia.
Advanced Animal Diagnostics is an animal health diagnostics company, developing highly accurate, rapid on-farm diagnostics. The QScout® line of on-farm diagnostics will detect disease states at an early stage and optimize management of the reproductive, nutritional and overall health status of production animals, beginning with the dairy cow. The company’s platform diagnostic technology is designed to enhance the profitability of livestock production, improve animal welfare, and ensure a safe, abundant supply of animal protein.
Adicet Bio, Inc. is using it’s novel immune cell therapy platform in combination with its wholly owned subsidiary, Applied Immune Technologies, Ltd.’s T-Cell Receptor-Like (TCRL) antibody platform that are targeted to intracellular-derived peptides to develop novel immunotherapies for inflammatory, autoimmune and infectious diseases as well as cancer.
Akouos is developing targeted therapies to restore and preserve hearing in genetically-defined patient populations.
AMP was founded in 2009 as a spin-out from Prof. Ralf Hoffmann’s laboratory at the University of Leipzig. AMP is developing the next generation of broad-spectrum Gram-negative antibiotics for the treatment of drug-resistant infections. It has been estimated that approximately 30-40% of all hospital-acquired (nosocomial) infections worldwide are caused by Gram-negative bacteria. Gram-negative pathogens are highly genetically flexible and thus develop resistance mechanisms that render most of the current therapies ineffective.
Anokion is developing targeted therapeutics by retraining white blood cells to induce therapeutic antigen-specific immune tolerance. Their technology uses the body’s natural immune regulation by engineering proteins to be perceived as "self" entities to treat autoimmune and allergic diseases and to reduce the immunogenicity of therapeutic proteins.
Binx Binx Health is creating new categories of healthcare solutions that put on-demand testing where people need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer digital offerings, Binx is redefining "convenient care" for the modern consumer.
Atlas is developing the io® platform, a highly novel molecular diagnostic system for the ultra-rapid diagnosis of a broad range of infectious diseases using either nucleic acid or immunoassays. The system is fast, ultra-sensitive and designed for use in decentralized laboratories, point-of-care and other near-patient settings, providing a laboratory accurate test result in about 30 minutes.
E-scape is developing therapeutics against genetic targets for neurodegenerative disease including Alzheimer’s Disease, Parkinson’s Disease and Lysosomal storage diseases. E-scape’s small molecule approach binds to mutated protein targets and alters protein structure to mimic wild type functionality.
Exo Therapeutics is developing small-molecule enzyme inhibitors that target distal binding pockets (exo-sites) to reprogram enzyme activity with a focus on high value oncology indications.
Forendo is a drug discovery and development company with core competence in tissue specific regulation of sex hormone effects. Its two first-in-class product candidates are in preclinical development with the potential to offer significant therapeutic benefits in men’s and women’s health.
Forma targets essential cancer pathways to create small molecule cancer therapies. Forma leverages the integration of its innovative drug discovery technologies and oncology expertise, enabling efficient screening, discovery and rational development of drug candidates with qualified cellular mechanisms of action. Forma is building a robust pipeline of cancer therapies in areas such as tumor metabolism, proteinprotein interactions and epigenetics.
FoRx Therapeutics focusses on the development of novel anticancer therapies by drugging molecular targets that are essential for cancer cells undergoing DNA replication stress.
ImaginAb has a proprietary antibody fragment platform that yields molecular information to guide treatment decisions in cancer and immunology by in vivo imaging. ImaginAb also collaborates with biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies.
ImmPACT is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy. Its technology seeks to address the need to differentiate cancerous from non-cancerous tissues impacting the safety of the treatment which is to date a major limitation in reaching effectiveness.
Immunitas Therapeutics employs a single cell genomics platform to dissect the biology of immune cells in human tumors, thereby advancing findings directly from the bench into meaningful clinical improvements. The Immunitas focus on human data allows us to start with and stay closer to the biology that is most relevant in patients and greatly accelerates the pace of our research. Our team of scientific pioneers innovates around each step of the drug development process, first identifying novel targets, then designing therapeutic strategies, and developing key biomarkers to guide the selection of patients who may benefit from our new drugs.
Inflazome is developing first in class, orally available drugs to address clinical unmet needs by targeting activation of the inflammasome. The company has proprietary new chemical entities that inhibit inflammasome-driven release of pro-inflammatory cytokines that exacerbate inflammation. In addition, they block innate immune cell pyroptosis (uncontrolled cell death), a process that leads to chronic inflammation.
Intersection is developing a device to help monitor and manage patients in acute decompensated heart failure. A large and growing cost driver for healthcare systems, acute decompensated heart failure and related hospital re-admissions is a growing area of focus globally. Intersection looks to improve patient outcomes, inform the treatment paradigm, and reduce costs for healthcare systems.
Merganser Biotech is developing new medicines that increase hepcidin activity for the treatment of rare hematological and iron overload diseases. Hepcidin is the master regulator of iron metabolism and controls iron absorption from the diet and iron transfer around the body. Hepcidin deficiency causes iron overload, leading to heart and liver damage and may contribute to the severity of ineffective erythropoiesis and anemia in beta thalassemia. Merganser's hepcidin mimetic peptides prevent iron accumulation and reduce the severity of ineffective erythropoiesis in preclinical models of beta thalassemia.
At Zikani, we start with a rational approach to designing Ribosome Targeting Molecules (RTMs) that expands the structural diversity of these molecules. Our goal is to develop breakthrough RTMs that are orally delivered, safe and potent for the most difficult diseases.
Neurovance is a biopharmaceutical company developing treatments for central nervous system (CNS) disorders. Neurovance’s clinical stage EB-1020 for adult attention deficit hyperactivity disorder (ADHD) is a norepinephrine and dopaminepreferring triple reuptake inhibitor that is expected to be effective for adult ADHD without the addiction potential of other ADHD drugs.
Ra uses proprietary combinatorial assembly and in vitro display technologies to discover macrocyclic compounds with enhanced bioavailability targeting a wide range of intracellular, cell-surface, and circulating proteins. Ra’s initial focus is on orally available replacements for a variety of marketed biologics, as well as drugs targeting intracellular protein-protein interactions.
Trellis is leveraging its proprietary CellSpotTM technology to deliver higher quality therapeutic monoclonal antibodies. The company has programs in infectious disease.
Altimmune is a clinical stage immunotherapeutic biotechnology company focused on the discovery and development of novel products that engage, stimulate and improve immune responses for the prevention and treatment of disease. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Altimmune is able to rationally design and rapidly develop immunotherapeutic products tailored to address the a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer with fundamental advantages over competing products.
Annexon is developing disease modifying therapeutics to protect neuronal connections (synapses) that are lost in nearly all forms of neurodegenerative disease. Annexon’s platform is focused on inhibiting C1q as the initiating molecule of the complement cascade responsible for aberrantly binding to functional synapses and triggering their elimination in neurodegenerative diseases. This pathway is also well known to contribute to pathology in a number of autoimmune diseases of the nervous system. Annexon’s lead molecule, ANX005, effectively blocks this pathway and will have broad therapeutic application in both acute and chronic neurological diseases. Annexon’s initial focus will be in acute peripheral immune-mediated disorders.
Artios Pharma Limited is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer.
TScan Therapeutics is focused on developing novel therapeutics in immuno-oncology. Using its innovative platform technology, TScan is extending the promise of T cell-based treatments to patients with few therapeutic options.
Twentyeight-Seven Therapeutics is a focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases.
Covagen AG was acquired by Johnson & Johnson in 2014.
Acorda Therapeutics completed a public offering (NASDAQ: ACOR) in 2006.
Ra Pharmaceuticals completed a public offering (NASDAQ: RARX) in 2016.
Neurovance was acquired by Otsuka Pharmaceuticals in 2017.
Aerpio Therapeutics completed a public offering (NASDAQ:ARPO) in 2017.
Nabriva completed a public offering (NASDAQ: NBRV) in 2015.
Akebia Therapeutics completed a public offering (NASDAQ: AKBA) in 2014.
Alios BioPharma was acquired by Johnson & Johnson in 2014.
Celladon completed a public offering (NASDAQ: CLDN) in 2014.
Covagen was acquired by Cilag CmbH, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, in 2014.
Tokai Pharmaceuticals completed a public offering (NASDAQ: TKAI) in 2014.
Okairos was acquired by GlaxoSmithKline in 2013.
PharmAbcine Inc. completed a public offering (KOSDAQ) in 2018.
Avila Therapeutics was acquired by Celgene Corp. in 2012.
Intellikine was acquired by Takeda Pharmaceutical Company Ltd. in 2012.
LigoCyte Pharmaceuticals was acquired by Takeda Pharmaceutical Company Ltd. In 2012.
Cellerix completed a reverse merger into listed Tigenix BV (NYSE: TIG) in 2011.
EraGen Biosciences was acquired by Luminex Corporation in 2011.
Cequent Pharmaceuticals was acquired by MDRNA (now Marina Biotech) in 2010.
Evolva Holding completed a reverse merger into listed Arpida AG (SIX: EVE) in 2010.
FoldRx Pharmaceuticals was acquired by Pfizer, Inc. in 2010.
Forma Therapeutics completed a public offering (NASDAQ: FMTX) in 2020.
Akouos completed a public offering (NASDAQ: AKUS) in 2020.
Galera Therapeutics completed a public offering (NASDAQ:GRTX) in 2019.
Neovacs completed a public offering (Alternext Paris: ALNEV) in 2010.
Ablation Frontiers was acquired by Medtronic, Inc. in 2009.
ESBATech was acquired by Alcon in 2009.
Swiss Pharma Contract was acquired by Covance, Inc. in 2009.
Visiogen was acquired by Abbott Laboratories in 2009.
Adenosine Therapeutics was acquired by Clinical Data, Inc. in 2008.
Aeglea Biotherapeutics completed a public offering (NASDAQ: AGLE) in 2016.
Sirtris Pharmaceuticals completed a public offering (NASDAQ: SIRT) in 2007 and was acquired by GlaxoSmithKline in 2008.
Speedel Holding completed a public offering (SWX: SPPN) in 2005 and was acquired by Novartis in 2008.
Acorda Therapeutics completed a public offering (NASDAQ: ACOR) in 2006.
Infinity Pharmaceuticals completed a reverse merger into Discovery Partners, Inc. (NASDAQ: INFI) in 2006.
KuDOS Pharmaceuticals was acquired by AstraZeneca in 2006.
Heptares Therapeutics, Ltd was acquired by Sosei Group Corporation in 2015.
Miikana Therapeutics was acquired by EntreMed, Inc. (now CASI Pharmaceuticals, Inc.) in 2006.
Symetis was acquired by Boston Scientific in 2017.
Syrxx was acquired by Takeda Pharmaceutical Company Ltd. In 2006.
Torrey Pines Therapeutics completed a reverse merger into Axonyx (NASDAQ: TPTX) in 2006.
CombinatorRx completed a public offering (NASDAQ: CRXX) in 2005.
GlycArt Biotechnology was acquired by F. Hoffmann-La Roche Ltd. In 2005.
Silence Therapeutics completed a public offering (LON: SLN) in 2005.
Transform Pharmaceuticals was acquired by Johnson & Johnson in 2005.
Xenoport completed a public offering (NASDAQ: XNPT) in 2005.
Eyetech Pharmaceuticals completed a public offering (NASDAQ: EYET) in 2004.
Idenix Pharmaceuticals completed a public offering (NASDAQ: IDIX) in 2004.
Kinetix Pharmaceuticals was acquired by Amgen in 2004.
Theravance completed a public offering (NASDAQ: THRX) in 2004.
Cytos Biotechnology completed a public offering (SWX: CYTN) in 2002.
IsoTis OrthoBiologics completed a public offering (SWX: ISON) in 2000.
Discovery Technologies was acquired by Discovery Partners in 1999.
Proteostasis Therapeutics completed a public offering (NASDAQ: PTI) in 2016.
Qurient completed a public offering (KOSDAQ: 115180) in 2016.
Altimmune, Inc. completed a reverse merger into listed PharmAthene, Inc. (NASDAQ: ALT) in 2017.
BioNano Genomics completed a public offering (NASDAQ: BNGO) in 2018.
Cavion was acquired by Jazz Pharmaceuticals in 2019.
Viamet Clinical-stage antifungal portfolio acquired by NovaQuest Capital Management in 2018.
Genedata AG GeneData acquired NVF’s stake in the company in 2019.
Aileron Therapeutics completed a public offering (NASDAQ) in 2017.
Gensight Biologics completed a public offering (Euronext) in 2016.
Merus completed a public offering ((NASDAQ) in 2016.
Bicycle Therapeutics completed a public offering (NASDAQ: BCYC) in 2019.
We are stage agnostic (seed to commercial companies) and invest in multiple therapeutic areas where there is clear unmet medical need. Our first step in the process is to review non-confidential information about the company, team, technology / data, financial and exit plan. The further evaluation of business proposals is then based on confidential presentations by the management team that starts the full due diligence process.
Investments by the Novartis Venture Fund are made as equity participation typically as the lead or co-lead investor in a syndicate with a board seat.
Please contact one of our offices closest to the company site for an initial review. We have offices in Basel, Switzerland and Cambridge, MA, USA and entrepreneurs should contact the office closest to their company.